Clinical Trial

Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses

Unknown Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
Concurrent vaccination scheduling for key target populations in Rwanda, such as healthcare workers, may confer significant advantages in the provision of vaccine coverage to several infectious diseases. This is a phase IV vaccine trial that looks to establish if two licenced vaccines, the rVSVΔG-ZEBOV-GP vaccine for protection against Ebola virus and messenger ribonucleic acid (mRNA) COVID vaccine for protection against SARS-CoV-2 virus, given concurrently to self selected healthy adult volunteers confers an acceptable safety profile and immunogenicity response.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06587503
Lead Sponsor University of Birmingham
Collaborators: Project San Francisco, Rwanda Biomedical Centre, Merck Sharp & Dohme LLC
Conditions Ebola Virus Disease, COVID-19
Enrollment 72 participants
Start Date 2024-10
Primary Completion 2024-12 (estimated)
Study Completion 2025-05 (estimated)
Updated on ClinicalTrials.gov 2024-09-19